Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer

被引：1

作者：

Yu, Zhigang ^{[1
]}

机构：

[1] Shandong Univ, Hosp 2, Dept Breast Surg, 247 Beiyuan St, Jinan 250033, Peoples R China

来源：

TRANSLATIONAL BREAST CANCER RESEARCH | 2024年 / 5卷

关键词：

Immune-checkpoint inhibitors (ICIs); triple-negative breast cancer (TNBC); tislelizumab; cTRIO;

D O I：

10.21037/tbcr-23-39

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页数：5

共 19 条

[1] Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019 [J].

Burstein, H. J. ;

Curigliano, G. ;

Loibl, S. ;

Dubsky, P. ;

Gnant, M. ;

Poortmans, P. ;

Colleoni, M. ;

Denkert, C. ;

Piccart-Gebhart, M. ;

Regan, M. ;

Senn, H. -J. ;

Winer, E. P. ;

Thurlimann, B. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1541-1557

[2] Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 [J].

Cao, Wei ;

Chen, Hong-Da ;

Yu, Yi-Wen ;

Li, Ni ;

Chen, Wan-Qing .

CHINESE MEDICAL JOURNAL, 2021, 134 (07) :783-791

[3]

chictr, ChiCTR2100041675

[4] Pathogenesis of Triple-Negative Breast Cancer [J].

Derakhshan, Fatemeh ;

Reis-Filho, Jorge S. .

ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2022, 17 :181-204

[5] Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis [J].

Gao, Chundi ;

Li, Huayao ;

Liu, Cun ;

Xu, Xiaowei ;

Zhuang, Jing ;

Zhou, Chao ;

Liu, Lijuan ;

Feng, Fubin ;

Sun, Changgang .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[6] Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study* [J].

Gianni, L. ;

Huang, C. S. ;

Egle, D. ;

Bermejo, B. ;

Zamagni, C. ;

Thill, M. ;

Anton, A. ;

Zambelli, S. ;

Bianchini, G. ;

Russo, S. ;

Ciruelos, E. M. ;

Greil, R. ;

Semiglazov, V ;

Colleoni, M. ;

Kelly, C. ;

Mariani, G. ;

Del Mastro, L. ;

Maffeis, I ;

Valagussa, P. ;

Viale, G. .

ANNALS OF ONCOLOGY, 2022, 33 (05) :534-543

[7]

Gonzalez-Ericsson PI, The path to a better biomarker: application of a risk

[8] PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study [J].

Huang, Guili ;

Liu, Songqing ;

Dong, Jie ;

Xi, Xin ;

Kong, Rui ;

Li, Wenjun ;

Du, Qian .

FRONTIERS IN PHARMACOLOGY, 2022, 13

[9] Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification [J].

Li, Jianbin ;

Jiang, Zefei .

CANCER BIOLOGY & MEDICINE, 2022, 19 (06) :769-773

[10]

National Bureau of Statistics of China, 2020, China Statistical Yearbook

← 1 2 →